Ma Luyao, Qin Xiaobing, Yu Aoyang, Liu Haonan, Pan Di, Gao Ying, Wu Zichen, Chen Zihan, Han Zhengxiang
The Affiliated Hospital of Xuzhou Medical University, Quanshan District, No. 99 West Huaihai Road, Xuzhou, Jiangsu, China.
Clin Transl Oncol. 2025 Mar;27(3):1092-1104. doi: 10.1007/s12094-024-03677-0. Epub 2024 Aug 30.
The purpose of this meta-analysis was to examine the clinicopathological and prognostic significance of tertiary lymphocytic infiltrates in lung cancer.
A systematic search was performed in many databases, including PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wangfangdate, and CBM, up until January 2024. We calculated the hazard ratio (HR), odds ratios (OR), and confidence interval (CI), and accomplished this meta-analysis with Stata 15 software.
14 studies, including 3101 patients, were subjected to analysis. High TLS detection was associated with a longer OS (HR = 0.545, 95% CI: 0.359-0.827, p = 0.004), DFS (HR = 0.431, 95% CI: 0.350-0.531, p < 0.001), and RFS (HR = 0.430, 95% CI: 0.325-0.569, p < 0.001). Meanwhile, it was observed that a higher detection of TLS was significantly correlated with the administration of adjuvant chemotherapy (OR = 1.505, 95% CI: 1.017-2.225, p = 0.041). Not only that, but there was a higher occurrence of significantly elevated TLS detection in the early N stages (N = 0) compared to the advanced N stages (N = 1, 2, and 3) (OR = 1.604, 95% CI: 1.021-2.521, p = 0.04).
Elevated detection of TLS has been observed to be correlated with extended OS, DFS, and RFS in cases of lung cancer. This finding suggests that TLS could potentially serve as a valuable prognostic biomarker for lung cancer.
本荟萃分析旨在探讨肺癌中三级淋巴细胞浸润的临床病理及预后意义。
截至2024年1月,在多个数据库中进行了系统检索,包括PubMed、Web of Science、Cochrane图书馆、Embase、中国知网、万方数据和中国生物医学文献数据库。我们计算了风险比(HR)、比值比(OR)和置信区间(CI),并使用Stata 15软件完成了本荟萃分析。
对14项研究(共3101例患者)进行了分析。高TLS检测与更长的总生存期(HR = 0.545,95%CI:0.359 - 0.827,p = 0.004)、无病生存期(HR = 0.431,95%CI:0.350 - 0.531,p < 0.001)和复发-free生存期(HR = 0.430,95%CI:0.325 - 0.569,p < 0.001)相关。同时,观察到TLS检测率较高与辅助化疗的使用显著相关(OR = 1.505,95%CI:1.017 - 2.225,p = 0.041)。不仅如此,与晚期N期(N = 1、2和3)相比,早期N期(N = 0)中TLS检测显著升高的发生率更高(OR = 1.604,95%CI:1.021 - 2.521,p = 0.04)。
已观察到肺癌病例中TLS检测升高与总生存期、无病生存期和复发-free生存期延长相关。这一发现表明TLS可能是一种有价值的肺癌预后生物标志物。